Busulfan

白消安

Report date: 2025/01/07 14:46:47
NME

Base Information

Drug NameBusulfan
Drug Alias Name布苏尔芬Busulphan不育磺busulfano白舒非 +[25] 
ClassificationSmall molecules
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsAdenosine deaminase deficiencyCNS Embryonal TumorSevere Combined Immunodeficiency +[20] 
Global Approved IndicationsMyeloproliferative DisordersLeukemia, Myelogenous, ChronicHematopoietic stem cell transplantation (HSCT)
Approved Indications in ChinaMyeloproliferative DisordersLeukemia, Myelogenous, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date1954/06/26
Country/TerritoryCanadaUnited StatesEU +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAspen Pharma
China Registration ClassN/A

Develop Information

Active CompaniesTrading As Aspen PharmacareWaylis Therapeutics LLCCatherine Bollard Children'S Research Institute +[10] 
Inactive CompaniesUtah State UniversityNational Institutes Of HealthShanghai Jiao Tong University School of Medicine +[7] 
Active IndicationsSevere Combined ImmunodeficiencyX-Linked Combined Immunodeficiency DiseasesMyeloproliferative Disorders +[7] 
Inactive IndicationsAdenosine deaminase deficiencyCNS Embryonal TumorGranulomatous Disease, Chronic +[13] 

Other Information

ATC CodeL01AB01
Related LinksWikipediaDrugBankKEGG